Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs supplies a comprehensive range of anti-TNFRSF13C recombinant antibody products for customers worldwide and provides extensive assistance throughout the research process from experimental design to troubleshooting challenges. We prioritize your research success by providing timely answers to questions regarding product application, storage, and handling. In addition, we offer vital validation data and personalized protocols, equipping researchers with the tools needed for reliable and reproducible results.
The BAFF-receptor (BAFFR), encoded by the TNFRSF13C gene, is crucial for B cell survival, influencing protein synthesis and energy metabolism. The binding of BAFF to BAFFR activates pathways essential for the longevity of various B cell stages, from immature to mature cells. Research indicates that BAFF–BAFFR interaction is also vital for the persistence of memory B cells, autoimmune B cells, and malignant chronic lymphocytic leukemia (CLL) cells. Consequently, BAFF–BAFFR signaling significantly impacts immune responses and pathological conditions like autoimmunity and B-cell malignancies, making BAFFR a promising target for therapeutic strategies in these diseases.
B-Cell-Activating Factor Receptor; Tumor Necrosis Factor Receptor Superfamily, Member 13C; BAFF-R; CD268 Antigen; Prolixin; BAFF Receptor; TNFRSF13C; CD268; Tumor Necrosis Factor Receptor Superfamily; BLyS Receptor 3; BR3
B cell-activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of Baff in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain. It is thought that this receptor is the principal receptor required for BAFF-mediated mature B-cell survival.
Our line of anti-TNFRSF13C recombinant antibody products offers versatile formulations and conjugation possibilities to meet various experimental requirements. This includes monoclonal and polyclonal antibodies, antibody-drug conjugates (ADCs), and recombinant antibody fragments. Designed to boost efficacy and accuracy, these antibodies are invaluable tools for exploring TNFRSF13C’s role in autoimmunity and B cell malignancy and for developing targeted therapies. Below is a curated list of antibodies that successfully inhibit TNFRSF13C.
Table 1. Featured anti-TNFRSF13C recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOR-3611 | Rabbit Anti-TNFRSF13C Recombinant Antibody (clone DS3611AB) | Human | Rabbit IgG | IHC-P, ICC, IF |
MOB-1119z | Mouse Anti-TNFRSF13C Recombinant Antibody (clone 11G12) | Human | Mouse IgG1 | FC, IHC |
MOB-0886MZ | Recombinant Mouse Anti-Human TNFRSF13C Antibody (clone 22D2) | Human | Mouse antibody | FC, IHC-P |
HPAB-0741-CN | Human Anti-TNFRSF13C Recombinant Antibody | Human, Cynomolgus | Human IgG2 | ELISA, FC, Neut |
HPAB-AP472-YC | Human Anti-TNFRSF13C Recombinant Antibody | Human | Human IgG1, κ | ELISA |
At Creative Biolabs, we provide top-tier TNFRSF13C recombinant antibodies renowned for their stringent quality assurance and reliability. Our comprehensive quality assurance protocols guarantee that every product adheres to the highest benchmarks, providing outstanding reliability for scientists and medical professionals engaged in immunotherapy and cancer studies.
Our cutting-edge production platform for anti-TNFRSF13C recombinant antibodies utilizes genetically engineered cells to accurately produce and secrete antibodies targeting the TNFRSF13C protein. This method facilitates the scalable and cost-effective production of superior-quality antibodies.
Featured Anti-TNFRSF13C Recombinant Antibody Production Platforms
Fig.1 Milligram-scale anti-TNFRSF13C recombinant antibody production.
Fig.2 Gram-scale anti-TNFRSF13C recombinant antibody production.
At Creative Biolabs, we are committed to providing an extensive selection of superior anti-TNFRSF13C recombinant antibodies in multiple formats, empowering researchers with cutting-edge tools for their scientific inquiries.
Fig.3 Full-length anti-TNFRSF13C recombinant antibody production and modalities.
Table 2. Public drug targeting TNFRSF13C.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Phase III | Anti-TNFRSF13C (Tumor Necrosis Factor Receptor Superfamily Member 13C; CD268; BAFF-R) |
Cancer Immunotherapy Human Monoclonal Antibodies |
Chronic lymphocytic leukemia Hepatitis, autoimmune Hidradenitis suppurativa Idiopathic pulmonary fibrosis Inflammatory disorders Leukemia Multiple sclerosis, relapsing-remitting Nephritis, lupus Pemphigus vulgaris Rheumatoid arthritis Scleroderma, diffuse Sjogren syndrome Systemic lupus erythematosus Thrombocytopenia, immune (Purpura, idiopathic thrombocytopenic) Warm antibody autoimmune hemolytic anemia (WAIHA) |
MorphoSys Novartis (Originator) |
Phase I | Anti-TNFRSF13C (Tumor Necrosis Factor Receptor Superfamily Member 13C; CD268; BAFF-R) |
Cancer Immunotherapy Monoclonal Antibodies |
Lymphoma, B-cell | Shanghai Escugen Biotechnology (Originator) |
Phase I | Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) |
Hematologic-blood cancer | Mayo Clinic (Originator) |
Phase I |
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI) Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269) Signal Transduction Modulators |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) |
Lymphoma, mantle cell Multiple myeloma Non-Hodgkin lymphoma Sjogren syndrome |
Case Western Reserve University (Originator) Luminary Therapeutics (Originator) |
Phase I | Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
B-cell acute lymphocytic leukemia Cancer Lymphoma, B-cell |
City of Hope (Originator) City of Hope National Medical Center (City of Hope) PeproMene Bio University of Texas System (Originator) |
Phase I |
Fc Fusion Proteins Polypeptides, from 41 AA |
Rheumatoid arthritis |
Biogen (Originator) Genentech (Originator) Roche |
|
Preclinical |
Anti-CLEC4C (C-Type Lectin Domain Family 4 Member C; BDCA2) Drugs Targeting Tumor Necrosis Factor Ligand Superfamily Member 13 (TNFSF13; APRIL) Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) |
Fusion Proteins Humanized Monoclonal Antibodies Polypeptides, from 41 AA |
Autoimmune disease | Nanjing Leads Biolabs (Originator) |
Preclinical | Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Lymphoma, mantle cell | University of Oxford (Originator) |
Preclinical |
Drugs Targeting B-Lymphocyte Antigen CD19 Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Acute lymphocytic leukemia | Beckman Research Institute City of Hope (Originator) |
Preclinical |
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI) Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R) Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269) |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Cancer | Case Western Reserve University (Originator) |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Creative Biolabs provides a wide array of high-quality anti-TNFRSF13C recombinant antibodies, customized to suit diverse research needs. From high-throughput production to bespoke smaller-scale projects, our expert team guarantees the highest quality products, prompt delivery, and outstanding customer service. Contact us today to discover more about our anti-TNFRSF13C antibodies and the ways we can assist your research efforts.